Vectibix (panitumumab)

P1/2, N=90, Recruiting, Isofol Medical AB | Trial completion date: Mar 2029 --> Dec 2029 | Trial primary completion date: Mar 2028 --> Nov 2028 | N=60 --> 90

P2, N=7, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | N=43 --> 7 | Trial primary completion date: Jul 2028 --> May 2026

We applied SSP to tumor tissues from participants with head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma who received the antibody panitumumab-IRDye800 in phase 1 trials. SSP identified pronounced spatial heterogeneity in single-cell drug delivery and target engagement, shaped by conserved stromal barriers, including periostin-rich extracellular matrix assemblies and fibroblast-activation-protein-positive cancer-associated fibroblast neighborhoods, which were associated with reduced antibody delivery in both tumor types. SSP measures drug-target-TME interactions in human tumors and can support studies of resistance mechanisms, dosing strategies and discovery of spatial biomarkers for precision oncology.

P=N/A, N=500, Active, not recruiting, Barretos Cancer Hospital

To address this, we developed a photoimmunodiagnostic-therapeutic conjugate (PPC) based on panitumumab and the near-infrared photosensitizer IR808, aiming to integrate tumor-specific targeting, real-time fluorescence imaging, and synergistic therapy...Following light exposure, it significantly suppressed tumor growth through the synergistic effects of photodynamic killing and immune activation without inducing notable systemic toxicity. This study offers a novel integrated diagnostic-therapeutic strategy for EGFR-positive malignancies, highlighting the photobiological mechanisms underlying its antitumor effects and demonstrating the potential of antibody-photosensitizer conjugates in photomedicine.

P2, N=43, Recruiting, Northwestern University | Trial completion date: Jul 2028 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028

In this MAIC analysis, soto960+pani demonstrated statistically significant improvement in response rates and OS in patients with chemorefractory KRAS G12C-mutated mCRC.

P2, N=214, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Mar 2026 --> Jun 2026

He subsequently developed liver metastases and was treated with FOLFIRI plus panitumumab...The regimen was switched to FOLFIRI plus bevacizumab, which achieved marked regression of all metastatic lesions...In colorectal cancer, repeat genetic testing of metastatic lesions should be considered, particularly in cases of treatment resistance. Molecular reassessment may reveal actionable alterations that guide therapy selection and optimize patient management.

P1, N=364, Recruiting, Astellas Pharma Inc

P2, N=300, Not yet recruiting, Federation Francophone de Cancerologie Digestive

P2, N=38, Active, not recruiting, Australasian Gastro-Intestinal Trials Group | Recruiting --> Active, not recruiting | N=90 --> 38 | Trial primary completion date: Apr 2026 --> Jan 2026